相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Empagliflozin in Patients with Chronic Kidney Disease
William G. Herrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes
Pasquale Mone et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories
Javed Butler et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)
Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes Heart Failure, and Atherosclerotic Cardiovascular Disease Insights From the Department of Veterans Affairs
Aliza Hussain et al.
JACC-HEART FAILURE (2023)
Cost-effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes
Bao-Ngoc Nguyen et al.
DIABETES OBESITY & METABOLISM (2023)
Functional and Clinical Importance of SGLT2-inhibitors in Frailty: From the Kidney to the Heart
Gaetano Santulli et al.
HYPERTENSION (2023)
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials
Hiddo J. L. Heerspink et al.
KIDNEY INTERNATIONAL (2023)
Empagliflozin in Patients with Chronic Kidney Disease
Brendon G. Neuen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial
Odette S. Reifsnider et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
Rahul Aggarwal et al.
CIRCULATION-HEART FAILURE (2022)
The effect of dapagliflozin on ventricular arrhythmias, cardiac arrest, or sudden death in people with heart failure: a tick in another box for sodium-glucose cotransporter 2 inhibitors
Theocharis Koufakis et al.
EXPERT OPINION ON PHARMACOTHERAPY (2022)
Cost-Effectiveness of Dapagliflozin for Non-diabetic Chronic Kidney Disease
Rebecca L. Tisdale et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2022)
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction JACC Review Topic of the Week
Jacob A. Udell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Cost-Effectiveness of Dapagliflozin for Chronic Kidney Disease in Japan
Satoshi Kodera et al.
CIRCULATION JOURNAL (2022)
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease A Health-Economic Analysis of DAPA-CKD
Phil McEwan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)
Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence
Peter Rossing et al.
KIDNEY INTERNATIONAL (2022)
Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis
Min Zhuo et al.
KIDNEY360 (2022)
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland
Anastasios Lymperopoulos et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Physician and Patient Adjustment to Reference Pricing for Drugs
James C. Robinson et al.
JAMA NETWORK OPEN (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
A Transparent and Consistent Approach to Assess US Outpatient Drug Costs for Use in Cost-Effectiveness Analyses
Joseph Levy et al.
VALUE IN HEALTH (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Number needed to treat (NNT) in clinical literature: an appraisal
Diogo Mendes et al.
BMC MEDICINE (2017)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Annualized was found better than absolute risk reduction in the calculation of number needed to treat in chronic conditions
TJ Mayne et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)
LB Zhou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2003)